---
document_datetime: 2025-12-29 14:36:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/copiktra.html
document_name: copiktra.html
version: success
processing_time: 0.1068825
conversion_datetime: 2025-12-30 02:53:26.983338
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Copiktra

[RSS](/en/individual-human-medicine.xml/67441)

##### Authorised

This medicine is authorised for use in the European Union

duvelisib Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Copiktra](#news-on)
- [More information on Copiktra](#more-information-on-copiktra-938)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Copiktra is a cancer medicine used to treat chronic lymphocytic leukaemia (CLL, a cancer of a type of white blood cells called B lymphocytes) and follicular lymphoma (another cancer that affects B lymphocytes).

In CLL, Copiktra is used in patients whose disease has either come back or not improved after at least two other treatments. In follicular lymphoma, it is used in patients whose disease has not improved after at least two other treatments.

Copiktra contains the active substance duvelisib.

Expand section

Collapse section

## How is Copiktra used?

Copiktra can only be obtained with a prescription and it should be prescribed by a doctor experienced in the use of cancer medicines.

Copiktra is available as capsules to be taken by mouth; the recommended dose is 25 mg twice a day. Treatment should be continued for as long as the patient improves or remains stable and the side effects are tolerable. The doctor may reduce the dose or stop treatment temporarily or permanently if certain side effects occur. The dose may also need to be reduced in patients taking other medicines that increase the amount of duvelisib in the body.

Any infection should be treated before starting treatment with Copiktra and patients should also be monitored for infection during Copiktra treatment.

For more information about using Copiktra, see the package leaflet or contact your doctor or pharmacist.

## How does Copiktra work?

The active substance in Copiktra, duvelisib, blocks the effects of certain enzymes (called PI3K-delta and PI3K-gamma) that are overactive in blood cancers. These enzymes enable the growth and survival of the cancer cells. By blocking the effects of the enzymes, duvelisib causes the cancer cells to die, thereby delaying or stopping the progression of the cancer.

## What benefits of Copiktra have been shown in studies?

A main leukaemia study showed that Copiktra was more effective than another cancer medicine, ofatumumab, in patients with CLL that had not improved or had come back after at least 2 other treatments. Among the 196 such patients in the study, those treated with Copiktra lived on average 16 months before the cancer got worse compared with 9 months in those treated with ofatumumab.

In a second main study of lymphoma, Copiktra was effective in producing a response in patients with follicular lymphoma whose cancer had not improved after 2 previous treatments: 40% of these patients (29 of 73) responded to treatment.

## What are the risks associated with Copiktra?

The most common side effects with Copiktra (which may affect more than 2 in 10 people) are diarrhoea or colitis (inflammation in the large bowel), neutropenia (low levels of neutrophils, a type of white blood cell), rash, tiredness, fever, cough, nausea (feeling sick), upper respiratory tract infection (nose and throat infection), pneumonia (infection of the lungs), musculoskeletal pain (pain in the muscle and bones) and anaemia (low red blood cell count).

The most common serious side effects were pneumonia, colitis and diarrhoea.

For the full list of side effects and restrictions with Copiktra, see the package leaflet.

## Why is Copiktra authorised in the EU?

Copiktra was shown to be effective in delaying worsening of the disease in patients with CLL that had not improved or had come back after at least 2 previous treatments. In addition, the medicine was effective in patients with follicular lymphoma that had not improved after at least 2 previous treatments. The safety of Copiktra was considered acceptable. The European Medicines Agency therefore decided that Copiktra's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Copiktra?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Copiktra have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Copiktra are continuously monitored. Side effects reported with Copiktra are carefully evaluated and any necessary action taken to protect patients.

## Other information about Copiktra

Copiktra received a marketing authorisation valid throughout the EU on 19 May 2021

Copiktra : EPAR - Medicine overview

Reference Number: EMA/242496/2021

English (EN) (140.04 KB - PDF)

**First published:** 31/05/2021

[View](/en/documents/overview/copiktra-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-785)

български (BG) (132.9 KB - PDF)

**First published:**

31/05/2021

[View](/bg/documents/overview/copiktra-epar-medicine-overview_bg.pdf)

español (ES) (110.5 KB - PDF)

**First published:**

31/05/2021

[View](/es/documents/overview/copiktra-epar-medicine-overview_es.pdf)

čeština (CS) (130.97 KB - PDF)

**First published:**

31/05/2021

[View](/cs/documents/overview/copiktra-epar-medicine-overview_cs.pdf)

dansk (DA) (108.8 KB - PDF)

**First published:**

31/05/2021

[View](/da/documents/overview/copiktra-epar-medicine-overview_da.pdf)

Deutsch (DE) (112.87 KB - PDF)

**First published:**

31/05/2021

[View](/de/documents/overview/copiktra-epar-medicine-overview_de.pdf)

eesti keel (ET) (98.74 KB - PDF)

**First published:**

31/05/2021

[View](/et/documents/overview/copiktra-epar-medicine-overview_et.pdf)

ελληνικά (EL) (135.46 KB - PDF)

**First published:**

31/05/2021

[View](/el/documents/overview/copiktra-epar-medicine-overview_el.pdf)

français (FR) (111.75 KB - PDF)

**First published:**

31/05/2021

[View](/fr/documents/overview/copiktra-epar-medicine-overview_fr.pdf)

hrvatski (HR) (130.6 KB - PDF)

**First published:**

31/05/2021

[View](/hr/documents/overview/copiktra-epar-medicine-overview_hr.pdf)

italiano (IT) (108.61 KB - PDF)

**First published:**

31/05/2021

[View](/it/documents/overview/copiktra-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (140.91 KB - PDF)

**First published:**

31/05/2021

[View](/lv/documents/overview/copiktra-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (131.5 KB - PDF)

**First published:**

31/05/2021

[View](/lt/documents/overview/copiktra-epar-medicine-overview_lt.pdf)

magyar (HU) (130.66 KB - PDF)

**First published:**

31/05/2021

[View](/hu/documents/overview/copiktra-epar-medicine-overview_hu.pdf)

Malti (MT) (132.81 KB - PDF)

**First published:**

31/05/2021

[View](/mt/documents/overview/copiktra-epar-medicine-overview_mt.pdf)

Nederlands (NL) (108.55 KB - PDF)

**First published:**

31/05/2021

[View](/nl/documents/overview/copiktra-epar-medicine-overview_nl.pdf)

polski (PL) (135.54 KB - PDF)

**First published:**

31/05/2021

[View](/pl/documents/overview/copiktra-epar-medicine-overview_pl.pdf)

português (PT) (110.27 KB - PDF)

**First published:**

31/05/2021

[View](/pt/documents/overview/copiktra-epar-medicine-overview_pt.pdf)

română (RO) (129.93 KB - PDF)

**First published:**

31/05/2021

[View](/ro/documents/overview/copiktra-epar-medicine-overview_ro.pdf)

slovenčina (SK) (129.25 KB - PDF)

**First published:**

31/05/2021

[View](/sk/documents/overview/copiktra-epar-medicine-overview_sk.pdf)

slovenščina (SL) (128.6 KB - PDF)

**First published:**

31/05/2021

[View](/sl/documents/overview/copiktra-epar-medicine-overview_sl.pdf)

Suomi (FI) (107.57 KB - PDF)

**First published:**

31/05/2021

[View](/fi/documents/overview/copiktra-epar-medicine-overview_fi.pdf)

svenska (SV) (108.12 KB - PDF)

**First published:**

31/05/2021

[View](/sv/documents/overview/copiktra-epar-medicine-overview_sv.pdf)

Copiktra : EPAR - Risk-management-plan summary

English (EN) (119.9 KB - PDF)

**First published:** 31/05/2021

[View](/en/documents/rmp-summary/copiktra-epar-risk-management-plan-summary_en.pdf)

## Product information

Copiktra : EPAR - Product information

English (EN) (561.02 KB - PDF)

**First published:** 31/05/2021

**Last updated:** 03/04/2025

[View](/en/documents/product-information/copiktra-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-163)

български (BG) (641.53 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/bg/documents/product-information/copiktra-epar-product-information_bg.pdf)

español (ES) (564.27 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/es/documents/product-information/copiktra-epar-product-information_es.pdf)

čeština (CS) (613.02 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/cs/documents/product-information/copiktra-epar-product-information_cs.pdf)

dansk (DA) (549.51 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/da/documents/product-information/copiktra-epar-product-information_da.pdf)

Deutsch (DE) (582.62 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/de/documents/product-information/copiktra-epar-product-information_de.pdf)

eesti keel (ET) (552.29 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/et/documents/product-information/copiktra-epar-product-information_et.pdf)

ελληνικά (EL) (645.71 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/el/documents/product-information/copiktra-epar-product-information_el.pdf)

français (FR) (584.03 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/fr/documents/product-information/copiktra-epar-product-information_fr.pdf)

hrvatski (HR) (620.03 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/hr/documents/product-information/copiktra-epar-product-information_hr.pdf)

íslenska (IS) (577.02 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/is/documents/product-information/copiktra-epar-product-information_is.pdf)

italiano (IT) (553.78 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/it/documents/product-information/copiktra-epar-product-information_it.pdf)

latviešu valoda (LV) (624.21 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/lv/documents/product-information/copiktra-epar-product-information_lv.pdf)

lietuvių kalba (LT) (630.77 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/lt/documents/product-information/copiktra-epar-product-information_lt.pdf)

magyar (HU) (640.13 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/hu/documents/product-information/copiktra-epar-product-information_hu.pdf)

Malti (MT) (665.31 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/mt/documents/product-information/copiktra-epar-product-information_mt.pdf)

Nederlands (NL) (578.38 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/nl/documents/product-information/copiktra-epar-product-information_nl.pdf)

norsk (NO) (565.86 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/no/documents/product-information/copiktra-epar-product-information_no.pdf)

polski (PL) (650.47 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/pl/documents/product-information/copiktra-epar-product-information_pl.pdf)

português (PT) (557.57 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/pt/documents/product-information/copiktra-epar-product-information_pt.pdf)

română (RO) (664.68 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/ro/documents/product-information/copiktra-epar-product-information_ro.pdf)

slovenčina (SK) (658.59 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/sk/documents/product-information/copiktra-epar-product-information_sk.pdf)

slovenščina (SL) (645.3 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/sl/documents/product-information/copiktra-epar-product-information_sl.pdf)

Suomi (FI) (555.07 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/fi/documents/product-information/copiktra-epar-product-information_fi.pdf)

svenska (SV) (553.22 KB - PDF)

**First published:**

31/05/2021

**Last updated:**

03/04/2025

[View](/sv/documents/product-information/copiktra-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0007/G 10/08/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Copiktra : EPAR - All authorised presentations

English (EN) (18.56 KB - PDF)

**First published:** 31/05/2021

[View](/en/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-433)

български (BG) (60.43 KB - PDF)

**First published:**

31/05/2021

[View](/bg/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_bg.pdf)

español (ES) (49.01 KB - PDF)

**First published:**

31/05/2021

[View](/es/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_es.pdf)

čeština (CS) (47.92 KB - PDF)

**First published:**

31/05/2021

[View](/cs/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (50.31 KB - PDF)

**First published:**

31/05/2021

[View](/da/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.45 KB - PDF)

**First published:**

31/05/2021

[View](/de/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (49.42 KB - PDF)

**First published:**

31/05/2021

[View](/et/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (64.85 KB - PDF)

**First published:**

31/05/2021

[View](/el/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_el.pdf)

français (FR) (49.2 KB - PDF)

**First published:**

31/05/2021

[View](/fr/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (56.36 KB - PDF)

**First published:**

31/05/2021

[View](/hr/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (19.18 KB - PDF)

**First published:**

31/05/2021

[View](/is/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_is.pdf)

italiano (IT) (48.5 KB - PDF)

**First published:**

31/05/2021

[View](/it/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (72.55 KB - PDF)

**First published:**

31/05/2021

[View](/lv/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (66.8 KB - PDF)

**First published:**

31/05/2021

[View](/lt/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (66.1 KB - PDF)

**First published:**

31/05/2021

[View](/hu/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (65.93 KB - PDF)

**First published:**

31/05/2021

[View](/mt/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (49.34 KB - PDF)

**First published:**

31/05/2021

[View](/nl/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (18.91 KB - PDF)

**First published:**

31/05/2021

[View](/no/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_no.pdf)

polski (PL) (67.27 KB - PDF)

**First published:**

31/05/2021

[View](/pl/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_pl.pdf)

português (PT) (48.91 KB - PDF)

**First published:**

31/05/2021

[View](/pt/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_pt.pdf)

română (RO) (55.54 KB - PDF)

**First published:**

31/05/2021

[View](/ro/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (56.94 KB - PDF)

**First published:**

31/05/2021

[View](/sk/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (56.94 KB - PDF)

**First published:**

31/05/2021

[View](/sl/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (48.53 KB - PDF)

**First published:**

31/05/2021

[View](/fi/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (49.31 KB - PDF)

**First published:**

31/05/2021

[View](/sv/documents/all-authorised-presentations/copiktra-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Copiktra Active substance duvelisib International non-proprietary name (INN) or common name duvelisib Therapeutic area (MeSH)

- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Follicular

Anatomical therapeutic chemical (ATC) code L01EM04

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Copiktra monotherapy is indicated for the treatment of adult patients with:

- Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies.
- Follicular lymphoma (FL) that is refractory to at least two prior systemic therapies.

## Authorisation details

EMA product number EMEA/H/C/005381

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Secura Bio Limited

Secura Bio Limited

Opinion adopted 25/03/2021 Marketing authorisation issued 19/05/2021 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Copiktra : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (108.26 KB - PDF)

**First published:** 10/11/2021

**Last updated:** 03/04/2025

[View](/en/documents/procedural-steps-after/copiktra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Copiktra : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/236249/2021

English (EN) (9.83 MB - PDF)

**First published:** 31/05/2021

[View](/en/documents/assessment-report/copiktra-epar-public-assessment-report_en.pdf)

Copiktra : Orphan designation withdrawal assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-645386

English (EN) (1.5 MB - PDF)

**First published:** 31/05/2021

[View](/en/documents/orphan-maintenance-report/copiktra-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

CHMP summary of positive opinion for Copiktra

Adopted

Reference Number: EMA/CHMP/84697/2021

English (EN) (165.37 KB - PDF)

**First published:** 26/03/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-copiktra_en.pdf)

#### News on Copiktra

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-march-2021) 26/03/2021

#### More information on Copiktra

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-13-1125) on 26 April 2013. The product was withdrawn from the Union Register of orphan medicinal products by the European Commission in March 2021 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-13-1157) on 17 July 2013. The product was withdrawn from the Union Register of orphan medicinal products by the European Commission in March 2021 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

**This page was last updated on** 03/04/2025

## Share this page

[Back to top](#main-content)